Phesi Introduces Health Check and Trial Rescue Service
Service expected to offer insights to sponsors conducting clinical trials in any indication in under ten days.
Phesi, a patient-centric data software and service provider, has officially launched its new health check and trial rescue service. The service works by leveraging Phesi’s AI-driven trial accelerator platform to assess protocols in terms of patient view, country view, site view and investigator view. Reportedly, the free of charge service will enable sponsors to submit their protocols to Phesi for a review, offering real-time insights and forecasting within ten working days.
“The clinical trials industry is facing a chronic challenge,” stated Gen Li, PhD, CEO, founder, Phesi. “Once a trial is underway, sponsors are often forced to amend the protocol to better align with the targeted patient population, often with millions of dollars on the line. Further, we know around a fifth of trials designed today will fail and that many “zombie” trials continue to run, mostly caused by inadequate protocol design. Phesi’s new Health Check and Trial Rescue Service addresses these issues by conquering two evergreen challenges: too many protocol amendments and too many failures to complete enrolment as planned. With this service, sponsors can take a proactive, data-driven approach – they won’t need to wait until a study is at risk of failing before they take action.”
Reference: Phesi launches Health Check and Trial Rescue Service to save at-risk trials and bring drugs to market faster. PharmiWeb. October 13, 2023. Accessed October 13, 2023. https://www.pharmiweb.com/press-release/2023-10-13/phesi-launches-health-check-and-trial-rescue-service-to-save-at-risk-trials-and-bring-drugs-to-market-faster#:~:text=Phesi's%20Health%20Check%20and%20Trial,trial%20planning%20and%20execution%20process
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
